This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Sturge–Weber syndrome | |
|---|---|
| Name | Sturge–Weber syndrome |
| Synonyms | encephalotrigeminal angiomatosis |
| Field | Neurology, Dermatology, Ophthalmology |
| Symptoms | port-wine stain, seizures, glaucoma, intellectual disability |
| Onset | Congenital |
| Duration | Lifelong |
| Causes | Somatic GNAQ mutation |
| Diagnosis | Clinical examination, imaging, genetic testing |
| Treatment | Antiepileptics, laser therapy, glaucoma surgery |
| Frequency | Rare |
Sturge–Weber syndrome is a rare congenital neurocutaneous condition characterized by facial capillary malformation, leptomeningeal vascular anomalies, and ocular involvement. First described in the 19th century, it presents with neurological, dermatological, and ophthalmological manifestations that require multidisciplinary care from specialists in Harvard Medical School, Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and other tertiary centers. Management involves collaboration among clinicians in National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, American Academy of Pediatrics, and specialty societies such as the American Academy of Neurology and American Academy of Ophthalmology.
Patients typically present with a unilateral facial capillary malformation (port-wine stain) involving distribution of the trigeminal nerve and associated leptomeningeal angiomas that produce seizures, hemiparesis, and developmental delays, often assessed by teams at Great Ormond Street Hospital, Boston Children's Hospital, Seattle Children's Hospital, Royal Children's Hospital, Melbourne, and Toronto SickKids Hospital. Cutaneous manifestations are frequently described alongside ocular hypertension, glaucoma, and choroidal hemangioma evaluated by clinicians at Bascom Palmer Eye Institute, Wills Eye Hospital, Cole Eye Institute, Moorfields Eye Hospital, and Scheie Eye Institute. Neurological findings include focal seizures, status epilepticus, migraine with aura, and progressive contralateral weakness that involve consultations with specialists affiliated with Cleveland Clinic, UCSF Medical Center, Stanford Health Care, NewYork-Presbyterian Hospital, and Mount Sinai Hospital. Cognitive impairment, behavioral disorders, and learning difficulties prompt involvement of neurodevelopmental teams at Kennedy Krieger Institute, Sheffield Children's Hospital, Great Ormond Street Hospital, Evelina London Children's Hospital, and Royal Hospital for Children, Glasgow.
The condition results from a postzygotic somatic activating mutation in the GNAQ gene leading to aberrant vascular development of dermal and leptomeningeal tissues, with molecular research conducted at institutions including Broad Institute, Sanger Institute, Cold Spring Harbor Laboratory, Dana-Farber Cancer Institute, and European Molecular Biology Laboratory. Pathophysiology involves capillary-venous malformations, abnormal angiogenesis, and impaired venous drainage causing chronic cortical hypoxia and calcification, phenomena studied in laboratories at Max Planck Society, Karolinska Institutet, Imperial College London, University of Tokyo, and University of Toronto. Investigations of downstream signaling implicate MAPK and PI3K pathways, with translational research partnerships among Novartis, Roche, Pfizer, GlaxoSmithKline, and academic centers such as Yale School of Medicine, Columbia University Irving Medical Center, and University College London.
Diagnosis is clinical, based on dermatologic findings and neurologic signs corroborated by neuroimaging modalities—contrast-enhanced MRI, susceptibility-weighted imaging, and CT—for assessment of leptomeningeal angiomas and calcifications used in protocols at Massachusetts General Hospital, Johns Hopkins Hospital, Mayo Clinic, UCSF Medical Center, and Karolinska University Hospital. Ophthalmologic evaluation with tonometry, gonioscopy, and optical coherence tomography is standard at Bascom Palmer Eye Institute, Wills Eye Hospital, Moorfields Eye Hospital, Cole Eye Institute, and Scheie Eye Institute to detect glaucoma and choroidal changes. Genetic testing for low-level somatic GNAQ mosaicism uses targeted sequencing and digital droplet PCR in laboratories at Broad Institute, Sanger Institute, NIH Clinical Center, Johns Hopkins University School of Medicine, and commercial diagnostic services affiliated with Quest Diagnostics and LabCorp.
Management is multidisciplinary and symptomatic, including antiepileptic drugs, epilepsy surgery, laser therapy for facial capillary malformations, glaucoma surgery, and rehabilitation coordinated across centers such as Cleveland Clinic, Mayo Clinic, Johns Hopkins Hospital, Great Ormond Street Hospital, and Boston Children's Hospital. Seizure control may employ drugs endorsed by guidelines from American Epilepsy Society, ketogenic diet programs at Johns Hopkins Hospital, vagus nerve stimulation from services at Duke University Hospital, and hemispherectomy procedures performed at Hospital for Sick Children, Toronto, Great Ormond Street Hospital, Necker–Enfants Malades Hospital, and UCLA Medical Center. Dermatologic laser treatment using pulsed dye laser is offered by dermatology departments at Mayo Clinic, Cleveland Clinic, Mount Sinai Hospital, Royal Free Hospital, and Guy's and St Thomas' NHS Foundation Trust. Ophthalmic management includes topical and surgical glaucoma interventions provided by teams at Bascom Palmer Eye Institute, Wills Eye Hospital, Moorfields Eye Hospital, King's College Hospital, and University College London Hospitals.
Long-term outcomes vary; many individuals experience refractory epilepsy, progressive hemiparesis, visual impairment, and cognitive deficits that necessitate lifelong care provided by services at National Health Service, Medicare, Children's Hospital of Philadelphia, Boston Children's Hospital, and Texas Children's Hospital. Complications include stroke-like episodes, secondary atrophy, intractable glaucoma, and psychosocial impacts managed through programs at National Institute of Neurological Disorders and Stroke, National Eye Institute, Child Mind Institute, Great Ormond Street Hospital, and Royal National Hospital for Rheumatic Diseases.
The syndrome is rare, with estimated prevalence approximately 1 in 20,000 to 50,000 live births, reported in population studies from United States Census Bureau datasets, surveillance reports by Centers for Disease Control and Prevention, cohort studies at Mayo Clinic, Johns Hopkins Hospital, Great Ormond Street Hospital, and registry efforts coordinated by European Rare Disease Network, National Organization for Rare Disorders, and Orphanet.
First clinical descriptions date to the late 19th century by clinicians whose work influenced pediatrics and neurology in institutions such as Guy's Hospital, St Thomas' Hospital, University College London, Johns Hopkins Hospital, and Massachusetts General Hospital; subsequent neuropathologic and imaging characterizations emerged through 20th-century advances at Peter Bent Brigham Hospital, Mayo Clinic, Harvard Medical School, Stanford University School of Medicine, and UCLA. Landmark molecular discoveries identifying GNAQ mutations were reported from collaborations among Broad Institute, Sanger Institute, Dana-Farber Cancer Institute, NIH Clinical Center, and university partners including University of California, San Francisco and University of British Columbia.
Current research explores targeted inhibitors of MAPK/ERK and PI3K/AKT signaling, antiangiogenic strategies, gene-editing approaches, and novel neuroprotective therapies investigated in trials at National Institutes of Health, academic consortia including European Molecular Biology Laboratory, pharmaceutical collaborations with Novartis, Roche, AstraZeneca, and multicenter trials run by networks such as Pediatric Brain Tumor Consortium, European Reference Networks, and registries supported by National Organization for Rare Disorders and Orphanet.